TY - JOUR AU - Liem, Xavier AU - de Baère, Thierry AU - Vivar, Omar I AU - Seiwert, Tanguy Y AU - Shen, Colette AU - Pápai, Zsuzsanna AU - Moreno, Victor AU - Takácsi-Nagy, Zoltán AU - Helferich, Frigyes AU - Thariat, Juliette AU - Gooi, Zhen AU - Yom, Sue S AU - Bossi, Paolo AU - Ferris, Robert L AU - Hackman, Trevor G AU - Le Tourneau, Christophe AU - Rodriguez, Joseph AU - Hoffmann, Caroline TI - International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers. JF - HEAD AND NECK : JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK J2 - HEAD NECK-J SCI SPEC VL - Apr 10. PY - 2024 SN - 1043-3074 DO - 10.1002/hed.27739 UR - https://m2.mtmt.hu/api/publication/34790124 ID - 34790124 AB - An international multidisciplinary panel of experts aimed to provide consensus guidelines describing the optimal intratumoral and intranodal injection of NBTXR3 hafnium oxide nanoparticles in head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, and cervical lymph nodes and to review data concerning safety, feasibility, and procedural aspects of administration.The Delphi method was used to determine consensus. A 4-member steering committee and a 10-member monitoring committee wrote and revised the guidelines, divided into eight sections. An independent 3-member reading committee reviewed the recommendations.After two rounds of voting, strong consensus was obtained on all recommendations. Intratumoral and intranodal injection was deemed feasible. NBTXR3 volume calculation, choice of patients, preparation and injection procedure, potential side effects, post injection, and post treatment follow-up were described in detail.Best practices for the injection of NBTXR3 were defined, thus enabling international standardization of intratumoral nanoparticle injection. LA - English DB - MTMT ER - TY - JOUR AU - Sipos, Miklós AU - Polgár, Csaba AU - Vesztergom, Dóra AU - Novák, Zoltán AU - Székely, Borbála AU - Masszi, András AU - Pintér, Tamás AU - Rubovszky, Gábor AU - Nánássy, László AU - Varga, Szilvia TI - A Belügyminisztérium egészségügyi szakmai irányelve a daganatos nőbetegek termékenységének megőrzéséről JF - EGÉSZSÉGÜGYI KÖZLÖNY J2 - EGÉSZSÉGÜGYI KÖZLÖNY VL - 74 PY - 2024 IS - 5 SP - 869 EP - 891 PG - 23 SN - 2063-1146 UR - https://m2.mtmt.hu/api/publication/34761802 ID - 34761802 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Molnár, Andrea AU - Pálfi, Erzsébet AU - Belák, Barbara AU - Blasszauer, Célia AU - Reibl, Dániel AU - Lövey, József TI - Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 30 PY - 2024 PG - 10 SN - 1219-4956 DO - 10.3389/pore.2024.1611664 UR - https://m2.mtmt.hu/api/publication/34744616 ID - 34744616 N1 - Health Sciences Division, Doctoral School of Semmelweis University, Budapest, Hungary Scientific Committee, National Association of Hungarian Dietitians, Budapest, Hungary Danone Hungary Kft., Budapest, Hungary Department of Dietetics and Nutritional Sciences, Semmelweis University, Budapest, Hungary Bacs-Kiskun County Hospital, Kecskemet, Hungary MedicalScan Kft., Budapest, Hungary National Tumour Biology Laboratory, National Institute of Oncology, Budapest, Hungary Department of Oncology, Semmelweis University, Budapest, Hungary Export Date: 19 April 2024 CODEN: POREF Correspondence Address: Molnár, A.; Health Sciences Division, Hungary; email: dr.molnarandrea.rd@gmail.com AB - Background: Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients’ nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. LA - English DB - MTMT ER - TY - JOUR AU - Hannoun-Levi, Jean-Michel AU - Gimeno Morales, Marta AU - Gal, Jocelyn AU - Anchuelo, Javier AU - Guinot, Jose-Luis AU - Gastanaga, Miren AU - Mészáros, Norbert AU - Polgár, Csaba AU - Strnad, Vratislav AU - Schiappa, Renaud AU - Gutierrez, Cristina TI - Very accelerated partial breast irradiation in 1 or 2 days. Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort. TS - Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort. JF - RADIOTHERAPY AND ONCOLOGY J2 - RADIOTHER ONCOL VL - 194 PY - 2024 PG - 7 SN - 0167-8140 DO - 10.1016/j.radonc.2024.110217 UR - https://m2.mtmt.hu/api/publication/34729969 ID - 34729969 N1 - Department of Radiation Oncology, Antoine Lacassagne Cancer Center, University Côte d'Azur, 33 avenue Valombrose, Nice Cedex 2, Nice, 06189, France Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain Department of Statistics, Antoine Lacassagne Cancer Center – University of Côte d'Azur, Nice, France Department of Radiation Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain Department of Radiation Oncology, Instituto Valenciano de Oncologia, Valencia, Spain Department of Radiation Oncology, Hospital Clínico San Carlos, Madrid, Spain National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary Department of Oncology, Semmelweis University, Budapest, Hungary Department of Radiation Oncology, Erlangen University Hospital, Erlangen, Germany Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain Export Date: 4 April 2024 CODEN: RAOND Correspondence Address: Hannoun-Levi, J.-M.; Radiation Oncology Department, 33 Avenue Valombrose, France; email: jean-michel.hannoun-levi@nice.unicancer.fr Chemicals/CAS: trastuzumab, 180288-69-1, 1446410-98-5 AB - To analyze late toxicity after very accelerated partial breast irradiation (VAPBI) for low-risk breast cancer.Methods: In this retrospective, observational, international multicenter study (HDH F20220713143949), patients with low-risk breast cancer underwent lumpectomy + vAPBI (high-dose rate multicatheter interstitial brachytherapy-MIBT). VAPBI was performed with 4(4x6.2Gy/2d), 3(3x7.45Gy/2d) or 1 fraction (1x16Gy or 1x18Gy/1d). Primary endpoint was late toxicity. Secondary endpoints were cumulative incidence of breast cancer local relapse (LR) and distant metastatic relapse (DMR) and specific (SS) and overall (OS) survivals. Prognostic factors for late toxicity were analyzed.From 01/2012 to 06/2022, 516 pts with early breast cancer were enrolled. Median follow-up was 44 months [95%CI 39-46]. Median age was 71 years [40-100]. Median tumor size was 12mm [1-35]. VAPBI delivered 1, 3 and 4 fractions for 205pts (39.7%), 167pts (32.4%) and 144pts (28%) respectively. 221 late toxicity events were observed in 168pts (32.6%) (Fibrosis, dyschromia, pain and telangiectasia). Grade 2 and 3 late toxicities were observed in 7.2 and 0.6% respectively (no G4) with no difference between 1 and ≥2 treatment days. CTV>50cc (p=0.007) and V150>40% (p=0.027) were prognostic factors for G≥2 late toxicity. Four-year cumulative incidence rates of LR and DMR were 2% [95%CI 0-3] and 1% [95%CI 0-2] respectively.VAPBI based on 1 or ≥2 days of MIBT represents an attractive de-escalation of irradiation approach for low-risk breast cancer. Late toxicity profile appears acceptable while early oncological outcome shows encouraging local control. Longer follow-up is warranted in order to confirm these preliminary results. LA - English DB - MTMT ER - TY - GEN AU - Gáldi, Ádám AU - Farkas, Gyöngyi AU - Gazdag-Hegyesi, Szilvia AU - Koszta, Enikő AU - Ágoston, Péter Zoltán AU - Pesznyák, Csilla AU - Major, Tibor AU - Takácsi-Nagy, Zoltán AU - Polgár, Csaba AU - Jurányi, Zsolt TI - Combined biological effects of CBCT and therapeutic X-ray dose on chromosomal aberrations of lymphocytes PY - 2024 UR - https://m2.mtmt.hu/api/publication/34669216 ID - 34669216 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Gesztesi, László AU - Kocsis, Zsuzsa AU - Jorgo, Kliton AU - Fröhlich, Georgina AU - Polgár, Csaba AU - Ágoston, Péter Zoltán TI - Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported Questionnaires JF - PROSTATE CANCER J2 - PROSTATE CANC VL - 2024 PY - 2024 PG - 13 SN - 2090-3111 DO - 10.1155/2024/5729185 UR - https://m2.mtmt.hu/api/publication/34544359 ID - 34544359 AB - The aim of the study was to compare the side effects of high-dose-rate brachytherapy (HDRBT) and low-dose-rate brachytherapy (LDRBT), with a particular focus on the effects on sexual functions and sexual well-being (PROMOBRA study, NCT02258087). Localized low-risk and low-intermediate-risk prostate cancer patients were treated with mono LDR (N = 123, 145 Gy dose) or mono HDR brachytherapy (N = 117, 19/21 Gy). Prior to the treatment and during follow-up (at 3, 6, 9, 12, 18, and 24 months after treatment, and then annually after two years), patients completed patient-reported outcome measurement (PROM) questionnaires EORTC QLQ-PR-25, International Index of Erectile Function (IIEF), and IIEF-5 (SHIM). We compared the patients in different group breakdowns (HDR vs. LDR, hormone naïve and hormone-receiving HDR vs. LDR, hormone naïve and hormone-receiving patients in general, and 19 Gy HDR vs. 21 Gy HDR). In the hormone-naive LDR group, erectile function, orgasm function, sexual desire, satisfaction with intercourse, and overall satisfaction functions significantly decreased compared to baseline throughout the whole follow-up period. However, there were significant decreases in function at a maximum of three time points after HDR therapy without hormone therapy. In hormone-receiving patients, the orgasm function was significantly better in the HDR group at multiple time points compared to the baseline, and sexual desire improved at four time points. According to our results, both LDRBT and HDRBT can be safely administered to patients with localized prostate cancer. In hormone-naive patients, the HDR group showed only recovering decreases in sexual functions, while the LDR group showed a lasting decline in multiple areas. Thus, HDR appears to be more advantageous to hormone-naive patients. LA - English DB - MTMT ER - TY - CONF AU - Sándor, Gyöngyvér Orsolya AU - Kocsis, Zsuzsa AU - Farkas, Gyöngyi AU - Vízkeleti, Júlia AU - Erdélyi, Borbála AU - Mészáros, Norbert AU - Lakosi, Ferenc AU - Végváry, Zoltán AU - Varga, Szilvia AU - Nguyen, Anhhong AU - Székely, Gábor AU - Takácsi-Nagy, Zoltán AU - Polgár, Csaba AU - Jurányi, Zsolt TI - Sugárérzékenység mérés cervix tumoros betegekben, a RILA módszer finomhangolása T2 - MST XVI. KONGRESSZUSA PY - 2023 SP - online UR - https://m2.mtmt.hu/api/publication/34574656 ID - 34574656 LA - Hungarian DB - MTMT ER - TY - GEN AU - Fodor, Martin AU - Kocsis, Zsuzsa AU - Sándor, Gyöngyvér Orsolya AU - Farkas, Gyöngyi AU - Vízkeleti, Júlia AU - Erdélyi, Borbála AU - Mészáros, Norbert AU - Lakosi, Ferenc AU - Végváry, Zoltán AU - Varga, Szilvia AU - Nguyen, Anhhong AU - Székely, Gábor AU - Takácsi-Nagy, Zoltán AU - Polgár, Csaba AU - Jurányi, Zsolt TI - RILA módszer laborgyakorlatba való bevezetése PY - 2023 UR - https://m2.mtmt.hu/api/publication/34554744 ID - 34554744 N1 - Előadás LA - Hungarian DB - MTMT ER - TY - GEN AU - Kocsis, Zsuzsa AU - Sándor, Gyöngyvér Orsolya AU - Rubovszky, Gábor AU - Székely, Borbála AU - Sávolt, Ákos AU - Smanykó, Viktor AU - Farkas, Gyöngyi AU - Székely, Gábor AU - Polgár, Csaba AU - Takácsi-Nagy, Zoltán AU - Jurányi, Zsolt TI - TNBC immun profil műtét/kemo/radioterápia után PY - 2023 UR - https://m2.mtmt.hu/api/publication/34554714 ID - 34554714 N1 - Előadás LA - Hungarian DB - MTMT ER - TY - GEN AU - Kocsis, Zsuzsa AU - Sándor, Gyöngyvér Orsolya AU - Farkas, Gyöngyi AU - Székely, Gábor AU - Rubovszky, Gábor AU - Székely, Borbála AU - Sávolt, Ákos AU - Smanykó, Viktor AU - Takácsi-Nagy, Zoltán AU - Polgár, Csaba AU - Jurányi, Zsolt TI - Előzetes eredmények prediktív immunológiai markerek kiválasztásához TNBC betegek esetében PY - 2023 UR - https://m2.mtmt.hu/api/publication/34554678 ID - 34554678 N1 - Előadás LA - Hungarian DB - MTMT ER -